Age-dependent pharmacokinetics of lamivudine in HIV-infected children

被引：24

作者：

Burger, D. M. ^{[1
]}

Verweel, G.

Rakhmanina, N.

Wissen, C. P. W. G. M. Verwey-Van

La Porte, C. J. L.

Bergshoeff, A. S.

Lyall, H.

Hartwig, N. G.

Green, H.

Soldin, S.

Gibb, D. M.

de Groot, R.

机构：

[1] Radboud Univ Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands

[2] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat, Rotterdam, Netherlands

[3] George Washington Univ, Childrens Natl Med Ctr, Dept Special Immunol Infect Dis, Washington, DC USA

[4] St Marys Hosp, Dept Pediat, London, England

[5] MRC, Clin Trials Unit, London, England

[6] Great Ormond St Hosp Sick Children, Dept Pediat, London, England

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷 / 04期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/sj.clpt.6100118

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The recommended dose of lamivudine in children is higher when compared with adults: 4 mg/kg vs similar to 2mg/kg (150 mg) and administered twice a day. Limited data are available to demonstrate that this increased dose results in adequate exposure to lamivudine in children with human immunodeficiency virus (HIV) infection. Data were selected from children who were using lamivudine for at least 2 weeks before a full pharmacokinetic (PK) study was conducted. Lamivudine PK parameters were significantly related to age. The age of 6 years appeared to be a cutoff for a change in PK parameters of lamivudine, with children < 6 years of age (n = 17) having a median area under the curve 43% lower and a median peak plasma concentration 47% lower (both P < 0.001) than older children (n = 34). In conclusion, further investigation of the relationship between decreased lamivudine exposure and treatment outcome and long-term resistance development in younger children with HIV infection is warranted.

引用

页码：517 / 520

页数：4

共 17 条

[11] Lamivudine in children with human immunodeficiency virus infection: A phase I/II study [J].

Lewis, LL ;

Venzon, D ;

Church, J ;

Farley, M ;

Wheeler, S ;

Keller, A ;

Rubin, M ;

Yuen, G ;

Mueller, B ;

Sloas, M ;

Wood, L ;

Balis, F ;

Shearer, GM ;

Brouwers, P ;

Goldsmith, J ;

Pizzo, PA ;

Anderson, B ;

Hirschfeld, S ;

Sei, S ;

Zeichner, S ;

Roilides, E ;

Clerici, M ;

Wells, M ;

Stocker, V ;

Higham, C ;

Townley, E ;

Walsek, C ;

Zwerski, S ;

Heilman, N ;

SelkinGutman, G ;

Wolters, P ;

Moss, H ;

Jarosinski, P .

JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (01) :16-25

[12] A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection [J].

McKinney, RE ;

Johnson, GM ;

Stanley, K ;

Yong, FH ;

Keller, A ;

O'Donnell, KJ ;

Brouwers, P ;

Mitchell, WG ;

Yogev, R ;

Wara, DW ;

Wiznia, A ;

Mofenson, L ;

McNamara, J ;

Spector, SA .

JOURNAL OF PEDIATRICS, 1998, 133 (04) :500-508

[13] Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children [J].

Mueller, BU ;

Lewis, LL ;

Yuen, GJ ;

Farley, M ;

Keller, A ;

Church, JA ;

Goldsmith, JC ;

Venzon, DJ ;

Rubin, M ;

Pizzo, PA ;

Balis, FM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) :3187-3192

[14] Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program [J].

Puthanakit, T ;

Oberdorfer, A ;

Akarathum, N ;

Kanjanavanit, S ;

Wannarit, P ;

Sirisanthana, T ;

Sirisanthana, V .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (01) :100-107

[15]

Strolin BM, 2003, FUND CLIN PHARM, V17, P281

[16] Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study [J].

van Leth, F ;

Phanuphak, P ;

Ruxrungtham, K ;

Baraldi, E ;

Miller, S ;

Gazzard, B ;

Cahn, P ;

Lalloo, UG ;

van der Westhuizen, IP ;

Malan, DR ;

Johnson, MA ;

Santos, BR ;

Mulcahy, F ;

Wood, R ;

Levi, GC ;

Reboredo, G ;

Squires, K ;

Cassetti, I ;

Petit, D ;

Raffi, F ;

Katlama, C ;

Murphy, RL ;

Horban, A ;

Dam, JP ;

Hassink, E ;

van Leeuwen, R ;

Robinson, P ;

Wit, FW ;

Lange, JMA .

LANCET, 2004, 363 (9417) :1253-1263

[17] Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography [J].

Verweij-Van Wissenab, CPWGM ;

Aarnoutse, RE ;

Burger, DM .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 816 (1-2) :121-129

← 1 2 →